PD-(L)1 inhibitor

BIOLOGICAL2 trials

Sponsors

Buzzard Pharmaceuticals, Peking University Cancer Hospital & Institute

Conditions

Collecting Duct CarcinomaSolid Tumor, Adult

Phase 1

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

CompletedNCT04121442

Buzzard PharmaceuticalsSolid Tumor, Adult

Start: 2020-09-01End: 2024-07-15Updated: 2024-08-06

Phase 2

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

RecruitingNCT06211114

Peking University Cancer Hospital & InstituteCollecting Duct Carcinoma

Start: 2024-02-09End: 2027-02-28Target: 30Updated: 2024-11-26

Related Papers

A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies.

Journal of Clinical Oncology2023-06-012 citations